BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CK-2017357: Phase II started

Cytokinetics began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate multiple ascending-doses of twice-daily oral CK-2017357 in about 24 ALS patients...

Read the full 86 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >